News Feature | Published:

Checkpoint inhibitors go viral

Nature Biotechnology volume 37, pages 1217 (2019) | Download Citation

Subjects

As clinical evidence mounts demonstrating the power of combining oncolytic viruses and checkpoint inhibitors, companies are scrambling to get in on the action.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Cell 170, 1109–1119.e10 (2017).

  2. 2.

    Nat. Rev. Drug Discov. 17, 86 (2018).

  3. 3.

    et al. Eur. J. Cancer 81, 116–129 (2017).

  4. 4.

    et al. Nat. Rev. Cancer 18, 313–322 (2018).

  5. 5.

    et al. J. Immunother. Cancer 5, 71 (2017).

  6. 6.

    et al. Oncogene 19, 2–12 (2000).

  7. 7.

    et al. J. Natl. Cancer Inst. 95, 652–660 (2003).

  8. 8.

    et al. Mol. Ther. 21, 620–628 (2013).

  9. 9.

    , , , & Trends Immunol. 39, 209–221 (2018).

  10. 10.

    et al. EBioMedicine 5, 59–67 (2016)

Download references

Author information

Affiliations

  1. London

    • Melanie Senior

Authors

  1. Search for Melanie Senior in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.4327

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing